1. Home
  2. SOAR vs REVB Comparison

SOAR vs REVB Comparison

Compare SOAR & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Volato Group Inc.

SOAR

Volato Group Inc.

HOLD

Current Price

$0.47

Market Cap

5.3M

Sector

Finance

ML Signal

HOLD

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$1.50

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOAR
REVB
Founded
2021
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
5.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SOAR
REVB
Price
$0.47
$1.50
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.4M
1.8M
Earning Date
03-30-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.32
N/A
Revenue
$58,312,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.39
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$1.41
52 Week High
$6.48
$54.48

Technical Indicators

Market Signals
Indicator
SOAR
REVB
Relative Strength Index (RSI) 36.98 55.26
Support Level $0.42 $1.41
Resistance Level $0.51 $1.67
Average True Range (ATR) 0.11 0.26
MACD 0.01 0.01
Stochastic Oscillator 8.95 54.59

Price Performance

Historical Comparison
SOAR
REVB

About SOAR Volato Group Inc.

Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Share on Social Networks: